Electrophysiological neuroimaging of the central effects of S-adenosyl-L-methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography

American Journal of Clinical Nutrition

Volumn 76, Issue 5, 2002, Pages

  Saletu, Bernd ^a   Anderer, Peter ^a   Di Padova, Carlo ^a   Assandri, Alessandro ^b   Saletu Zyhlarz, Gerda Maria ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Cross Research   (Switzerland)

Author keywords

Ademetionine; Antidepressants; Electroencephalogram mapping; Electrophysiological neuroimaging; Event related potentials mapping; Event related potentials tomography; LORETA; Low resolution brain electromagnetic tomography; S adenosyl L methionine; SAMe

Indexed keywords

ANTIDEPRESSANT AGENT; S ADENOSYLMETHIONINE;

ADULT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN MAPPING; BRAIN REGION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FEMALE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; NORMAL HUMAN; OCCIPITAL LOBE; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL; TEMPORAL LOBE;

EID: 0036830204     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/76.5.1162s     Document Type: Article

References (58)

1. Baldessarini RJ. Neuropharmacology of S-adenosyl-L-methionine. Am J Med 1987;83(suppl):95-103.
2. Stramentinoli G. Various pharmacological aspects of S-adenosylme-thionine: An overview. Cell Biol Rev 1987;S1:67-80.
3. Lieber CS, Casini A, De Carli LM, et al. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990;11:165-72.
4. Bressa GM. S-adenosyl-L-methionine (SAMe) as antidepressant: Meta-analysis of clinical studies. Acta Neurol Scand 1994; 154:7-14.
5. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: Comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002; 76(suppl):1172S-6S.
6. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr 2002; 76(suppl):1158S-61S.
7. Torta R, Borio R, Cicolin A, Vighetti S, Ravizza L. S-adenosyl-L-methionine normalizes P300 latency in patients with major depression. Curr Ther Res 1994:55:864-74.
8. Pascual-Marqui RD, Michel CM, Lehmann D. Low-resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int J Psychophysiol 1994;18:49-65.
9. Pascual-Marqui RD, Lehmann D, Koenig T, et al. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naïve, first-episode, productive schizophrenia. Psychiatry Res Neuroimaging 1999;90:169-79.
10. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Stuttgart, Germany: Thieme, 1988.
11. Anderer P, Saletu B, Kinsperger K, Semlitsch H. Topographic brain mapping of EEG in neuropsychopharmacology - Part 1. Methodological aspects. Methods Find Exp Clin Pharmacol 1987;9:371-84.
12. Buchsbaum MS, Hazlett E, Sicotte, Stein M, Wu J, Zetin M. Topographic EEG changes with benzodiazepine administration in generalized anxiety disorder. Biol Psychiatry 1985;20:832-42.
13. Duffy FH, Bartels PH, Burchfield JL. Significance probability mapping: An aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol 1981;51:455-62.
14. Itil TM, Shapiro DM, Eralp E, Akmann A, Itil KZ, Garbizu C. A new brain function diagnostic unit, including the dynamic brain mapping of computer analyzed EEG, evoked potentials and sleep (a new hardware/software system and its application in psychiatry and psychopharmacology), New Trends Exp Clin Psychiatry 1985; 1:107-77.
15. John ER, Prichep LS, Fridman J, Easton P. Neurometrics: Computer-assisted differential diagnosis of brain dysfunctions. Science 1988: 239:162-9.
16. Lehmann D. From mapping to the analysis and interpretation of EEG/EP maps. In: Maurer K, ed. Topographic Brain Mapping of EEG and Evoked Potentials. Berlin: Springer, 1989:53-75.
17. Saletu B. Visualizing the living human brain. The techniques and promise of EEG and event-related potentials mapping. In: Judd L, Saletu B, Filip V, eds. Basic and Clinical Science of Mental and Addictive Disorders. Basel: Karger, 1997:54-62.
18. Saletu B. Pharmacodynamics and EEG. I. From single-lead pharmaco-EEG to EEG mapping. In: Saletu B, Krijzer F, Ferber G, Anderer P, eds. Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields - An Update. Vienna: Facultas Universitätsverlag, 2000:139-56.
19. Saletu B, Anderer P, Kinsperger K, Grünberger J. Topographic brain mapping of EEG in neuropsychopharmacology - Part II. Clinical applications (Pharmaco EEG imaging). Methods Find Exp Clin Pharmacol 1987;9:385-408.
20. Saletu B, Anderer P, Pascual-Marqui RD. Pharmacodynamics and EEG. II. From EEG-mapping to EEG-tomography. In: Saletu B, Krijzer F, Ferber G, Anderer P, eds. Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields - An Update. Vienna: Facultas Universitätsverlag, 2000: 157-63.
21. Anderer P, Semlitsch HV, Saletu B, Barbanoj MJ. Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res 1992;45:79-93.
22. Abt K. Descriptive data analysis: A concept between confirmatory and exploratory data analysis. Methods Inf Med 1987;26:77-88.
23. Abt K. Descriptive data analysis (DDA) in quantitative EEG studies. In: Samson-Dollfus D, ed. Statistics and Topography in Quantitative EEG. Paris: Elsevier, 1988.
24. Abt K. Statistical aspects of neurophysiologic topography. J Clin Neurophysiol 1990;7:519-34.
25. Halgren E, Baudena P, Clarke JM, et al. Intracerebral potentials to rare target and distractor auditory and visual stimuli. 1. Superior temporal plane and parietal lobe. Electroencephalogr Clin Neurophysiol 1995;94:191-220.
26. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am J Psychiatry 1999;156:675-82.
27. Saletu-Zyhlarz GM, Anderer P, Assandri A, et al. Visualizing central effects of S-adenosyl-L-methionine (SAMe) - A natural molecule with antidepressant properties - By pharmaco-EEG mapping. Int J Neuropsychopharmacol 2002;5:199-215.
28. Saletu B, Anderer P, Lindeck-Pozza E, Assandri A, di Padova C, Saletu-Zyhlarz GM. Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine (SAMe) infusions in elderly subjects, utilizing EEG mapping and psychometry. J Neural Trans (in press).
29. Saletu B. Pharmaco-EEG profiles of typical and atypical antidepressants. In: Costa E, Racagni G, eds. Typical and Atypical Antidepressants: clinical practice. New York: Raven Press, 1982:257-68.
30. Saletu B, Grünberger J. Zur klassifikation und objektivierung der pharmakodynamik der antidepressiva. (Classifying and objectifying the pharmacodynamics of antidepressants.) In: Saletu B, Berner P, eds. Zyklothymie. (Cyclothymia.) Amsterdam: Excerpta Medica, 1983:103-26 (in German).
31. Saletu B, Grünberger J, Rajna P. Pharmaco-EEG profiles of antide-pressants. Pharmacodynamic studies with fluvoxamine. Br J Clin Pharmacol 1983;15:369-84.
32. Saletu B, Anderer P, Kinsperger K, Grünberger J, Musch B. On the central effects of the GABA agonist fengabine: Psychometric and pharmaco-EEG studies utilizing imaging methods. Drug Dev Res 1987;11:251-79.
33. Saletu B, Grünberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Phannacol 1992: 33:589-601.
34. Herrmann WM, Schärer E. Das pharmako-EEG und seine bedeu-tung für die klinische pharmakologie. (The pharmaco-EEG and its significance for clinical pharmacology.) In: Kuemmerle HP, Hitzenberger G, Spitzy KH, eds. Klinische Pharmakologie. (Clinical Pharmacology.) 4th Ed. Munich: Landsberg, 1986:1-71 (in German).
35. Barberi A, Pusateri C. Sugli effetti della S-adenosyl-metionina (SAMe) nelle sindromi depressive. [On the effects of S-adenosyl-methionine (SAMe) in depressive syndromes. J Estratto Minerva Psichiatr 1978;19:235-43 (in Italian).
36. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosyl-methionine treatment of depression: A controlled clinical trial. Am J Psychiatry 1988;145:1110-4.
37. Del Vecchio M, Iorio G, Cocorullo M, Vacca L, Amati A. Has SAMe an antidepressant effect? A preliminary trial versus chlorimipramine. Riv Sper Freniatr 1978;102:344-58.
38. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992;52:478-85.
39. Janicak PG, Lipinski J, Davis JM, et al. S-adenosyl-methionine in depression: A literature review and preliminary report. Ala J Med Sci 1988;25:306-31.
40. Küfferle B, Grünberger J. Early clinical double-blind study with S-adenosyl-L-methionine: A new potential antidepressant. In: Costa E, Racagni G, eds. Typical and Atypical Antidepressants: Clinical Practice. New York: Raven Press, 1982:175-80.
41. Mantero M, Pastorino P, Carolei A, Agnoli A. Studio controllato in doppio cieco (SAMe-imipramina) nelle sindromi depressive. [Controlled double-blind study (SAMe-imipramine) in depressive syndromes.] Estratto Minerva Med 1975;66:4098-101 (in Italian).
42. Miccoli L, Porro V, Bertolino A. Comparison between the antide-pressant activity of S-adenosyl-methionine (SAMe) and that of some tricyclic drugs. Estratto Acta Neurol 1978;33:243-55.
43. Scaggion G, Baldan L, Domanin S, et al. Azione antidepressiva della SAMe a confronto con il nomifensine maleato. (Antidepressive action of S-adenosylmethionine compared to nomifensine maleate.) Estratto Minerva Psichiatr 1982;23:93-7 (in Italian).
44. Scarzella R, Appiotti A. Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive. (Double-blind clinical comparison of SAMe and clomipramine in depressive syndromes.) Riv Sper Freniatr 1978;102:344-58 (in Italian).
45. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosyl-methionine for treatment of depression. Am J Psychiatry 1984:141:448-50.
46. Rosenbaum JF, Fava M, Falk WE. The antidepressant potential of oral S-adenosyl-methionine. Acta Psychiatr Scand 1990;81:432-6.
47. De Leo D. S-adenosyl-L-Methionine (SAMe) in clinical Practice: Preliminary report on 75 depressives. Curr Ther Res 1985;37:658-61.
48. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 1976;13:43-54.
49. Carney MWP. Review: Neuropharmacology of S-adenosyl-L-methionine. Clin Neuropharmacol 1986;9:235-43.
50. Caruso I, Fumagalli M, Bocassini L, et al. Treatment of depression in rheumatoid arthritic patients: A comparison of S-adenosyl-methionine (Samyr) and placebo in a double-blind study. Clin Trials J 1987;24: 305-10.
51. Fazio C, Andreoli V, Agnoli A, Casachia M, Cerbo R. Effetti terapeutici e meccanismo d'azione della S-adenosil-L-metionina (SAM) nelle sindromi depressive. [Therapeutic effects and mechanisms of action of S-adenosyl-L-methionine (SAMe) in depressive syndromes.] Minerva Med 1973;64:1515-29 (in Italian).
52. Muscettola G, Galzenati M, Balbi A. Same versus placebo: a double-blind comparison in major depressive disorders. In: Costa E, Racagni G, eds. Typical and Atypical Antidepressants: Clinical Practice. New York: Raven Press, 1982:151-6.
53. Kagan BL, Sultzer DL, Rosenlicht N, Gemer RH. Oral S-adenosyl-L-methionine in depression: A double-blind, placebo-controlled trial. Am J Psychiatry 1990;147:591-5.
54. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Gracie C. Double-blind placebo-controlled study of S-adenosyl-L-methionine in depressed post-menopausal women. Psychother Psychosom 1993;5:34-40.
55. Saletu B. Pharmacodynamics and EEG. In: Krijzer F, Hermann WM, eds. Advances in pharmaco-EEG. Practical and Theoretical Considerations in Preclinical and Clinical Studies. Berlin: Zentrale Universitätsdruckerei, Freie Universität Berlin, 1996:187-204.
56. Saletu B, Saletu M, Itil TM. Effect of tricyclic antidepressants on the somatosensory evoked potential in man. Psychopharmacologia 1973; 29:1-2.
57. R) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods. Neuropsychobiology 1997:36:130-52.
58. Coiro V, Vescovi PP. Controlled study of psychometric performance in abstinent alcoholics: Masked comparison of the effects of 15-day intravenous treatments with S-adenosylmethionine or normal saline. Curr Ther Res 1997;58:575-86.